SY-LB-57 is a highly effective agonist of bone morphogenetic protein (BMP) receptor signaling. SY-LB-57 can be used in studies of conditions such as bone fracture and pulmonary arterial hypertension [1].

SY-LB-57 (0.01-1000 μM, 24 h) can markedly induce cell proliferation at concentrations below 10 μM with an IC 50 value of 807.93 μM in C2C12 cells [1]. SY-LB-57 (0.01-10 μM, 15-30 min) increases the Smad protein phosphorylation and promotes p-Smad nuclear translocation, activates the PI3K/Akt pathway, and induces cytoplasmic localization of p-Akt [1]. SY-LB-57 (0.01-10 μM, 24 h) can induce cell cycle shift towards S and G2/M phases [1]. Cell Viability Assay [1] Cell Line: C2C12 cells Concentration: 0.01-1000 μM Incubation Time: 24 hours Result: Concentrations of 0.01–100 µM SY-LB-57 increased cell viability in C2C12 cells significantly compared with control by 280%, 290%, 200%, 150%, and 50% at 0.01 μM, 0.1 μM, 1 μM, 10 μM, and 100 μM, respectively. Western Blot Analysis [1] Cell Line: C2C12 cells Concentration: 0.01-10 μM Incubation Time: 15min or 30 min Result: strongly increased phosphorylation of Smad protein, 50% to 257% higher compared to control after 30 min. Showed a significant, robust increase in p-Akt expression levels over the control by 667-1081% after 15 min. Cell Cycle Analysis [1] Cell Line: C2C12 cells Concentration: 0.01-10 μM Incubation Time: 24 hours Result: Shifted the cell cycle in C2C12 cells toward proliferation causing a significant decline in the population of cells in G0/G1 phase and a sharp increase in the percentage of cells present in proliferative phases of the cell cycle (S and G2/M).